A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
Rigshospitalet, Denmark
Dana-Farber Cancer Institute
Stichting Hemato-Oncologie voor Volwassenen Nederland
Goethe University
St. Jude Children's Research Hospital
Barbara Ann Karmanos Cancer Institute
Institut Cancerologie de l'Ouest
University Hospital Southampton NHS Foundation Trust
Institute of Hematology & Blood Diseases Hospital, China
University of Liverpool
University Hospital Schleswig-Holstein
Western Sydney Local Health District
University Hospital Muenster